Concord Biotech Ltd. · NSE:CONCORDBIO
Concord Biotech — Q2 FY27 Earnings Presentation
28 slides from Concord Biotech's earnings presentation, October 2026
Slide 1: Investor Presentation – September 2026
Investor Presentation – September 2026
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Concord Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secur
Slide 3: Concord Biotech Investor Presentation Q2 & H1 FY27
CONCORD BIOTECH LIMITED Investor Presentation Q2 & H1 FY27 October 2026
Slide 4: Q2FY27 Key Highlights
Q2FY27 Key Highlights Broad based Growth Expansion into Dermatology with the Launch of Inspira 1 • Witnessed broad based growth across All Product Categories & 5 • Launched new dermatology division, Inspira, expanding presence across Geographies into dermatology with a portfolio of science-led skin
Slide 5: Q2 & H1FY27 Consolidated Financial Highlights
Q2 & H1FY27 Consolidated Financial Highlights Revenue (Rs. in Crs) EBITDA (Rs. in Crs) PAT (Rs. in Crs) +26% +25% +19% 566.6 186.8 127.3 +25% 451.1 +18% 149.9 +10% 107.1 309.1 104.4 63.1 69.6 247.1 88.5 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Gross Profit
Slide 6: Q2 & H1FY27 Segment Wise Revenue Split
Q2 & H1FY27 Segment Wise Revenue Split API Revenue (Rs. in Crs) Formulation Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) +36% +26% -8% 469.1 105.5 566.6 97.5 +30% 345.6 +6% +25% 451.1 250.2 55.3 58.9 309.1 191.8 247.1 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1
Slide 7: Q2 & H1FY27 Geography Wise Revenue Split
Q2 & H1FY27 Geography Wise Revenue Split Domestic Revenue (Rs. in Crs) Exports Revenue (Rs. in Crs) Total Revenue (Rs. in Crs) +27% +23% +26% 314.6 252.0 566.6 +42% 246.9 204.1 451.1 +8% +25% 178.7 130.4 309.1 121.1 247.1 126.0 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2FY26 Q2FY27 H1
Slide 8: Management Commentary
Management Commentary Commenting on Q2FY27 performance Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer said: “We are pleased to report strong year-on-year revenue growth of 25% in Q2FY27, driven by broad-based performance across product categories and geographies. Margins were marg
Slide 9: Q2 & H1FY27 Consolidated Profit & Loss Account
Q2 & H1FY27 Consolidated Profit & Loss Account Profit and Loss (Rs. in Crs) Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YoY Revenue from Operations 309.1 247.1 25.1% 566.6 451.1 25.6% Cost of Goods Sold 73.6 49.0 127.9 94.1 Gross Profit 235.5 198.0 18.9% 438.7 356.9 22.9% Gross Profit Margin 76.2% 80.2% 77.4% 7
Slide 10: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (in Rs. Crs) Sept-26 Mar-26 Equity & Liabilities (in Rs. Crs) Sept-26 Mar-26 Non - Current Assets 1,036.3 984.6 Total Equity 2,071.9 2,015.1 Property Plant & Equipment's 759.6 785.7 Share Capital 10.5 10.5 CWIP 111.7 78.2 Other Equity 2,065.3 2,006.6 Intangible asse
Slide 11: Abridged Consolidated Cashflow Statement
Abridged Consolidated Cashflow Statement Particulars (in Rs. Crs) H1FY27 H1FY26 Net Profit Before Tax 173.8 144.4 Adjustments for: Non -Cash Items / Other Investment or Financial Items 20.9 11.7 Operating profit before working capital changes 194.7 156.1 Changes in working capital -26.8 -56.9 Cash g
Slide 12: Company Overview
Company Overview Four manufacturing facilities in Ahmedabad, Gujarat, India, producing fermentation-based APIs and Finished Formulations API API FORMULATION INJECTABLES FACILITY FACILITY FACILITY FACILITY Dholka Limbasi Valthera Valthera Ahmedabad, Gujarat Ahmedabad, Gujarat Ahmedabad, Gujarat Ahmed
Slide 13: Concord Biotech at a Glance
Concord Biotech at a Glance An R&D-driven biopharma company manufacturing Active Pharmaceutical Ingredients (APIs) through fermentation & semi- synthetic processes, and finished formulations 30+ 150+ 180+ 7 1,250m³ Fermentation APIs in the Drug Master Files (DMFs) filed Approved formulation products
Slide 14: Driving Innovation Through Our Expertise
Driving Innovation Through Our Expertise Mission Focus 1 Quality products that enhance human health, built on lasting partnerships Fermentation Expertise Strong fermentation capability delivering 2 high-quality APIs Diversified Portfolio 3 Immunosuppressants, oncology & anti- infectives: 30+ ferment
Slide 15: API Business Overview
API Business Overview Leading global developer & Niche APIs, backward-integrated to Diversified across manufacturer of fermentation APIs key starting materials Immunosuppressants, Oncology, Anti- Infectives, Anti -Fungal Key products Across five therapy areas Immunosuppressant 8 APIs Oncology 8 APIs
Slide 16: Formulation Business Overview
Formulation Business Overview Since 2016, leveraging backward Presence in regulated & emerging Orals (tablets, capsules, softgel, Oral integration from our APIs markets. Branded Generics in India suspension) & Injectables Key brands Across four therapy areas Antibiotics CRITICAL CARE Antifungal CRIT
Slide 17: Trusted CDMO Partner for Fermentation & Semi-Synthetic APIs
Trusted CDMO Partner for Fermentation & Semi-Synthetic APIs DSIR AMPLE CAPACITIES Prioritizes innovation, backed Over 1250 M3 of Fermentation by a DSIR-certified R&D capacity for consistent & facility uninterrupted supplies CDMO Fermentation & semi- synthetic APIs REGULATORY APPROVALS TEAM Necessary
Slide 18: Pushing Boundaries through Manufacturing Capabilities
Pushing Boundaries through Manufacturing Capabilities Four facilities in Gujarat, built step by step over 25 years of expansion FY2025 UNIT IV · INJECTABLES · FY2021 VALTHERA FY2016 UNIT III · API · LIMBASI 36,441 sq.m. Site area 5,96,309 sq.m. FY2000 UNIT II · FORMULATIONS · VALTHERA Site area INJE
Slide 19: Pioneering R&D Capabilities
Pioneering R&D Capabilities R&D spend (₹ Cr) % of sales R&D initiatives R&D IN NUMBERS 26 30 23 27 29 New product 194 01 02 Cost improvement development R&D employees Process Technology 03 04 150+ improvement transfer API DMFs filed Scale-up Backward 05 initiatives 06 integration 12 / 7 2022 3.6% 20
Slide 20: DMF Filings Across Geographies
DMF Fillings Across Geographies Molecules US EU Canada Japan China Tacrolimus ✓ ✓ ✓ ✓ ✓ Mycophenolate Mofetil ✓ ✓ ✓ ✓ ✓ Suppressants Mycophenolate Sodium ✓ ✓ ✓ ✓ Immuno- Cyclosporine ✓ ✓ ✓ ✓ ✓ Sirolimus ✓ ✓ ✓ ✓ Pimecrolimus ✓ Voclosporin ✓ Temsirolimus ✓ ✓ Everolimus ✓ ✓ ✓ ✓ Oncology Romidepsin ✓ ✓
Slide 21: Wide Range of Formulation Products for US & Global Markets
Wide Range of Formulation Products for US & Global Markets 7 12 UNITED STATES EMERGING MARKETS MARKET FOOTPRINT ANDA approved products Products Key market presence United States Mycophenolate Mofetil Capsules Mycophenolate Mofetil Capsules LATAM Mycophenolate Mofetil Tablets Mycophenolic Acid DR Tab
Slide 22: Diversified Customer Base
Diversified Customer Base 70+ 300+ Countries Customers Reducing Customer Concentration % Contribution from Top 10 Customers FY26 37.6% 37.8% FY25 42.0% FY24 FY23 44.3% Worldwide Presence Tailored Distribution Models FY22 47.7% Collaborative Partnerships
Slide 23: Paving the Way for Sustainability
Paving the Way for Sustainability Our Vision for Sustainability The Path of Sustainability Sustainable Manufacturing Research & Development Efficient Resource Global Green Leadership Management Constant Improvement & Environmental Conservation Adaptation Awarded Silver Medal by EcoVadis Our Initiati
Slide 24: Key Business Differentiators
Key Business Differentiators
Slide 25: End-to-End Expertise in Complex Fermentation Value Chain
End-to-End Expertise in Complex Fermentation Value Chain 01 02 03 04 Leadership Over 2 1,250 M³ 30+ Fermented Position Decades Fermentation Capacity based API's Leadership position for Experience in the across two API One of leading global select molecules in industry with a facilities developers an
Slide 26: Constructing Formidable Barriers to Entry
Constructing Formidable Barriers to Entry Capital Intensive Operational Complex Process & Significant + Infrastructural + Requirements (large + Long gestation Period = Technical Expertise Entry Barriers Requirements scale fermenters) Complex technical capabilities, difficulties in scaling up operati
Slide 27: Key Growth Drivers
Key Growth Drivers API Business Expanding API Marketing existing Increasing wallet share Portfolio APIs to new with existing customers customers 1 Formulations Business Expanding portfolio Launching new dosage Expanding geographic CONCORD BIOTECH through own development forms including injectables r
Slide 28: For further Information, please contact
For further Information, please contact Company: Investor Relations Advisor: Concord Biotech Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24230GJ1984PLC007440 CIN - U74140MH2010PTC204285 Mr. Raviraj Karia – Chief Financial Officer ravirajkaria@concordbiotech.com Mr. Sagar Shroff / Mr. Krishna S